Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02647853 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers
A Phase 1 study of Lipodystrophy and Nasolabial Folds, sponsored by Topokine Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT02647853 is a Phase 1 study of Lipodystrophy and Nasolabial Folds that has completed, run by Topokine Therapeutics. The registered enrollment target is 16 participants, below the 132-participant average among 11 other Lipodystrophy trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02647853, a Phase 1 study of Lipodystrophy and Nasolabial Folds, has completed, sponsored by Topokine Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This Phase 1, randomized, placebo-controlled, double-blind, healthy volunteer study tested the safety, tolerability, and plasma pharmacokinetics of two different concentrations of TAT4 Gel administered once daily to 50 cm2 of skin for 14 days.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TAT4 Gel concentration A
- DRUG TAT4 Gel concentration B
Study Locations (1)
California
- Topokine Clinical Site - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02647853
The ClinicalTrials.gov registry entry for NCT02647853 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 132-participant average among 11 other Lipodystrophy trials with a reported enrollment target (88% lower). The listed sponsor is Topokine Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lipodystrophy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02647853 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02647853 about?
NCT02647853 is a clinical study titled "Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers". This Phase 1, randomized, placebo-controlled, double-blind, healthy volunteer study tested the safety, tolerability, and plasma pharmacokinetics of two different concentrations of TAT4 Gel administered once daily to 50 cm2 of skin for 14 days.
What is the current status of trial NCT02647853?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-10. Estimated completion is 2014-12.
What conditions does trial NCT02647853 study?
This clinical trial studies the following conditions: Lipodystrophy, Nasolabial Folds, Lipoatrophy.
What interventions are being tested in trial NCT02647853?
The interventions under investigation include: Placebo (DRUG), TAT4 Gel concentration A (DRUG), TAT4 Gel concentration B (DRUG).
Who is sponsoring clinical trial NCT02647853?
This trial is sponsored by Topokine Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02647853 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lipodystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy
RECRUITING
-
Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD)
RECRUITING
-
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
ACTIVE NOT RECRUITING · Phase 2
-
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension
COMPLETED · Phase 2
-
Exercise and Pioglitazone for HIV-Metabolic Syndromes
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.